Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Takeda continues to be the only manufacturer of immunoglobulin therapy with low IgA content less than or equal to 2 µg/mL in a 10% solution

  80% confidence

• GAMMAGARD LIQUID ERC underscores Takeda's ongoing dedication to providing differentiated therapeutic options to meet the varied needs of people with primary immunodeficiency, including those who require an option with low IgA content

  80% confidence

• Primary immunodeficiency affects about 1 in 1,200 people in the United States

  80% confidence

• GAMMAGARD LIQUID ERC shares the same state-of-the-art manufacturing process as the other liquid formulations in the Takeda IG portfolio, and features an Enhanced Removal Capability (ERC) to reduce the IgA content

  80% confidence

• As a ready-to-use liquid that does not require reconstitution and can be administered intravenously or subcutaneously, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and healthcare providers

  80% confidence

Cited in these Via News reports

• Takeda Phases Out Legacy IVIG Product as Global Immunoglobulin Market Shifts Toward Next-Generation Therapies →